Viatris Inc VTRS

NAS: VTRS | ISIN: US92556V1061 3/05/2024

11,78 USD (+1,55%)

(+1,55%) 3/05/2024

Grafiek Viatris Inc

Grafiek Viatris Inc

1 dag1d 1,55%
1 week1w 0,00%
1 maand1m 0,17%
3 maanden3m 1,73%
6 maanden6m 27,90%
1 jaar1j 30,60%
5 jaar5j -27,91%

donderdag 9 mei 2024, 13:00

Kwartaalcijfers (1ste kwartaal)

Viatris Inc in het nieuws

Toon enkel gratis nieuws

2 mei 2024 · Viatris to Participate in the BofA Securities 2024 Health Care Conference · Persbericht

1 mei 2024 · Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health · Persbericht

16 april 2024 · Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 · Persbericht

15 april 2024 · Viatris Appoints Corinne Le Goff as Chief Commercial Officer · Persbericht

1 april 2024 · Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States · Persbericht

27 maart 2024 · Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline · Persbericht

28 februari 2024 · Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance · Persbericht

28 februari 2024 · Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration · Persbericht

5 februari 2024 · Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results · Persbericht

21 december 2023 · Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

Profiel Viatris Inc

Gezondheidstechnologie

CEO: Michael Goettler

Werknemers: 12.348

Aandelen Viatris Inc

Beurswaarde: 13,81 miljard USD

Effecten: 1,19 miljard

Winst per aandeel (12 maand): PLUS

Koers-winstverhouding: PLUS

Beta: 0,74

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe